Biological therapy in elderly patients with acute myeloid leukemia
暂无分享,去创建一个
[1] J. Carulli,et al. Targeting RARA overexpression with tamibarotene, a potent and selective RARα agonist, is a novel approach in AML , 2022, Blood advances.
[2] S. de Botton,et al. Reduced Venetoclax Exposition to Seven Days of Azacitidine Is Efficient in Treatment-Naïve Patients with Acute Myeloid Leukemia , 2022, Blood.
[3] S. de Botton,et al. Update on a Phase 1/2 First-in-Human Study of the Menin-KMT2A (MLL) Inhibitor Ziftomenib (KO-539) in Patients with Relapsed or Refractory Acute Myeloid Leukemia , 2022, Blood.
[4] J. Dipersio,et al. The Menin Inhibitor SNDX-5613 (revumenib) Leads to Durable Responses in Patients (Pts) with KMT2A-Rearranged or NPM1 Mutant AML: Updated Results of a Phase (Ph) 1 Study , 2022, Blood.
[5] N. Kadowaki,et al. Cost-Effectiveness Analysis of Transplantation-Ineligible Elderly Patients With Acute Leukemia Harboring a Molecular Target: Ph-Positive Acute Leukemia and FLT3-Mutated Acute Myeloid Leukemia , 2022, Journal of clinical medicine research.
[6] R. Schlenk,et al. AML-029 Quizartinib Prolonged Overall Survival (OS) vs Placebo Plus Intensive Induction and Consolidation Therapy Followed by Single-Agent Continuation in Patients Aged 18-75 Years With Newly Diagnosed FLT3-Internal Tandem Duplication Positive (FLT3-ITD+) Acute Myeloid Leukemia (AML). , 2022, Clinical lymphoma, myeloma & leukemia.
[7] N. Daver,et al. Eprenetapopt in the Post-Transplant Setting: Mechanisms and Future Directions. , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] B. Seliger,et al. Underlying mechanisms of evasion from NK cells as rationale for improvement of NK cell-based immunotherapies , 2022, Frontiers in Immunology.
[9] J. Esteve,et al. Phase 3 Trial of Gilteritinib Plus Azacitidine Vs Azacitidine for Newly Diagnosed FLT3mut+ AML Ineligible for Intensive Chemotherapy. , 2022, Blood.
[10] J. Ritz,et al. Memory-like NK cells armed with a neoepitope-specific CAR exhibit potent activity against NPM1 mutated acute myeloid leukemia , 2022, Proceedings of the National Academy of Sciences of the United States of America.
[11] K. Pratz,et al. Cost-Effectiveness Analysis of Venetoclax in Combination with Azacitidine Versus Azacitidine Monotherapy in Patients with Acute Myeloid Leukemia Who are Ineligible for Intensive Chemotherapy: From a US Third Party Payer Perspective , 2022, PharmacoEconomics.
[12] J. Esteve,et al. P582: FIRST RESULTS OF A PHASE II STUDY (STIMULUS-AML1) INVESTIGATING SABATOLIMAB + AZACITIDINE + VENETOCLAX IN PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA , 2022, HemaSphere.
[13] P. Vyas,et al. AML-348 A Phase Ib/II Study of Ivosidenib With Venetoclax +/- Azacitidine in IDH1-Mutated Hematologic Malignancies. , 2022, Clinical lymphoma, myeloma & leukemia.
[14] P. Vyas,et al. Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in frontline TP53m AML patients: Phase 1b results. , 2022, Journal of Clinical Oncology.
[15] M. Konopleva,et al. Venetoclax resistance: mechanistic insights and future strategies , 2022, Cancer drug resistance.
[16] H. Döhner,et al. Ivosidenib and Azacitidine in IDH1-Mutated Acute Myeloid Leukemia. , 2022, The New England journal of medicine.
[17] M. Konopleva,et al. Idasanutlin plus cytarabine in relapsed or refractory acute myeloid leukemia: results of the MIRROS trial , 2022, Blood advances.
[18] R. Schubert,et al. Primary CD33-targeting CAR-NK cells for the treatment of acute myeloid leukemia , 2022, Blood Cancer Journal.
[19] Justin C. Boucher,et al. Emerging CAR T Cell Strategies for the Treatment of AML , 2022, Cancers.
[20] R. Larson,et al. Follow-up of patients with R/R FLT3-mutation–positive AML treated with gilteritinib in the phase 3 ADMIRAL trial , 2022, Blood.
[21] Thomas E. Hughes,et al. Pembrolizumab and decitabine for refractory or relapsed acute myeloid leukemia , 2018, Journal for ImmunoTherapy of Cancer.
[22] L. Ruggeri,et al. Long-Term Outcome After Adoptive Immunotherapy With Natural Killer Cells: Alloreactive NK Cell Dose Still Matters , 2022, Frontiers in Immunology.
[23] M. Tormo,et al. A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for older patients with AML , 2021, Blood advances.
[24] O. Griffith,et al. Donor Memory-like NK cells Persist and Induce Remissions in Pediatric Patients with Relapsed AML after Transplant. , 2021, Blood.
[25] M. Konopleva,et al. Phase I/II Study of Azacitidine (AZA) with Venetoclax (VEN) and Magrolimab (Magro) in Patients (pts) with Newly Diagnosed Older/Unfit or High-Risk Acute Myeloid Leukemia (AML) and Relapsed/Refractory (R/R) AML , 2021, Blood.
[26] M. Konopleva,et al. Safety and Efficacy from a Phase 1b/2 Study of IMGN632 in Combination with Azacitidine and Venetoclax for Patients with CD123-Positive Acute Myeloid Leukemia , 2021, Blood.
[27] J. Esteve,et al. Efficacy and Safety of Sabatolimab (MBG453) in Combination with Hypomethylating Agents (HMAs) in Patients (Pts) with Very High/High-Risk Myelodysplastic Syndrome (vHR/HR-MDS) and Acute Myeloid Leukemia (AML): Final Analysis from a Phase Ib Study , 2021, Blood.
[28] A. Stamatoullas,et al. Long Term Follow-up and Combined Phase 2 Results of Eprenetapopt (APR-246) and Azacitidine (AZA) in Patients with TP53 mutant Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia (AML) , 2021, Blood.
[29] G. Garcia-Manero,et al. Evorpacept (ALX148), a CD47-Blocking Myeloid Checkpoint Inhibitor, in Combination with Azacitidine: A Phase 1 / 2 Study in Patients with Myelodysplastic Syndrome (ASPEN-02) , 2021, Blood.
[30] J. Esteve,et al. Sabatolimab (MBG453) Combination Treatment Regimens for Patients (Pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS): The MDS Studies in the Stimulus Immuno-Myeloid Clinical Trial Program , 2021, Blood.
[31] P. Vyas,et al. A Phase 3, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination with Azacitidine in Previously Untreated Patients with TP53-Mutant Acute Myeloid Leukemia , 2021, Blood.
[32] M. Konopleva,et al. A Triplet Combination of Azacitidine, Venetoclax and Gilteritinib for Patients with FLT3-Mutated Acute Myeloid Leukemia: Results from a Phase I/II Study , 2021, Blood.
[33] M. Minden,et al. Enasidenib in Combination with Venetoclax in IDH2-Mutated Myeloid Malignancies: Preliminary Results of the Phase Ib/II Enaven-AML Trial , 2021, Blood.
[34] Jifeng Yu,et al. Targeting CD47 for cancer immunotherapy , 2021, Journal of Hematology & Oncology.
[35] H. Döhner,et al. Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial. , 2021, The Lancet. Oncology.
[36] D. Cella,et al. Patient-reported outcomes predict overall survival in older patients with acute myeloid leukemia. , 2021, Journal of geriatric oncology.
[37] J. Serody,et al. Phase II Trial of Pembrolizumab after High-Dose Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia. , 2021, Blood cancer discovery.
[38] K. Bogdanov,et al. AML-288: The Combination of Gemtuzumab Ozogamicin and Azacitidine in the Treatment of Relapsed and Refractory AML , 2021 .
[39] J. Serody,et al. Safety and efficacy of pembrolizumab prior to allogeneic stem cell transplant in Acute Myeloid Leukemia. , 2021, Transplantation and cellular therapy.
[40] J. Cortes,et al. CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial. , 2021, The Lancet. Haematology.
[41] M. Konopleva,et al. A phase 1b/2 study of azacitidine with PD‐L1 antibody avelumab in relapsed/refractory acute myeloid leukemia , 2021, Cancer.
[42] M. Andreeff,et al. Therapeutic implications of menin inhibition in acute leukemias , 2021, Leukemia.
[43] S. Piha-Paul,et al. Results of a phase 1 dose-escalation study of AMV564, a novel T-cell engager, alone and in combination with pembrolizumab in patients with relapsed/refractory solid tumors. , 2021 .
[44] M. Konopleva,et al. A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia or myelodysplastic syndrome , 2021, Haematologica.
[45] K. Laribi,et al. Impact of age, functional status, and comorbidities on quality of life and outcomes in elderly patients with AML: review , 2021, Annals of Hematology.
[46] M. Gurney,et al. Realizing Innate Potential: CAR-NK Cell Therapies for Acute Myeloid Leukemia , 2021, Cancers.
[47] M. Konopleva,et al. Nivolumab maintenance in high-risk acute myeloid leukemia patients: a single-arm, open-label, phase II study , 2021, Blood Cancer Journal.
[48] M. Konopleva,et al. Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia , 2021, Blood Cancer Journal.
[49] B. Falini,et al. CD123 Is Consistently Expressed on NPM1-Mutated AML Cells , 2021, Cancers.
[50] Jiqiang Yao,et al. Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[51] D. Ludwig,et al. 225Ac‐labeled CD33‐targeting antibody reverses resistance to Bcl‐2 inhibitor venetoclax in acute myeloid leukemia models , 2020, Cancer medicine.
[52] Jeffrey S. Miller,et al. GTB-3550 TriKE™ for the Treatment of High-Risk Myelodysplastic Syndromes (MDS) and Refractory/Relapsed Acute Myeloid Leukemia (AML) Safely Drives Natural Killer (NK) Cell Proliferation At Initial Dose Cohorts , 2020 .
[53] M. Berger,et al. Lintuzumab-225Ac in Combination with Venetoclax in Relapsed/Refractory AML: Early Results of a Phase I/II Study , 2020 .
[54] F. Ravandi,et al. Complete Responses in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients on a Weekly Dosing Schedule of Vibecotamab (XmAb14045), a CD123 x CD3 T Cell-Engaging Bispecific Antibody; Initial Results of a Phase 1 Study , 2020, Blood.
[55] M. Konopleva,et al. Quizartinib with Decitabine +/- Venetoclax Is Highly Active in Patients (Pts) with FLT3-ITD Mutated (mut) Acute Myeloid Leukemia (AML): Clinical Report and Signaling Cytof Profiling from a Phase IB/II Trial , 2020 .
[56] N. Daver,et al. Efficacy and Safety of Venetoclax in Combination with Gilteritinib for Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia in the Expansion Cohort of a Phase 1b Study , 2020 .
[57] Jeffrey S. Miller,et al. A trispecific killer engager molecule against CLEC12A effectively induces NK cell mediated killing of AML cells , 2020, Leukemia.
[58] T. Yau,et al. TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AML. , 2020, Blood advances.
[59] Jeffrey S. Miller,et al. Exploring the NK cell platform for cancer immunotherapy , 2020, Nature Reviews Clinical Oncology.
[60] S. Rutella,et al. Flotetuzumab as Salvage Immunotherapy for Refractory Acute Myeloid Leukemia. , 2020, Blood.
[61] J. Welch,et al. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. , 2020, The Lancet. Haematology.
[62] A. Letai,et al. Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. , 2020, The New England journal of medicine.
[63] G. Guyatt,et al. American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults. , 2020, Blood advances.
[64] P. Paschka,et al. Updated results from phase I dose-escalation study of AMG 330, a bispecific T-cell engager molecule, in patients with relapsed/refractory acute myeloid leukemia (R/R AML). , 2020 .
[65] P. Vyas,et al. Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in MDS and AML patients: Phase Ib results. , 2020 .
[66] N. Daver,et al. A phase Ib/II study of the CD123-targeting antibody-drug conjugate IMGN632 as monotherapy or in combination with venetoclax and/or azacitidine for patients with CD123-positive acute myeloid leukemia. , 2020 .
[67] High Risk Myelodysplastic Syndrome , 2020, Definitions.
[68] Qi Zhang,et al. Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML. , 2020, Blood.
[69] Y. Ishikawa,et al. FLT3 mutations in acute myeloid leukemia: Therapeutic paradigm beyond inhibitor development , 2019, Cancer science.
[70] R. Schlenk,et al. Single agent talacotuzumab demonstrates limited efficacy but considerable toxicity in elderly high-risk MDS or AML patients failing hypomethylating agents , 2019, Leukemia.
[71] R. Varadhan,et al. Multi-Center Phase 2 Study of Pembroluzimab (Pembro) and Azacitidine (AZA) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) and in Newly Diagnosed (≥65 Years) AML Patients , 2019, Blood.
[72] P. Sharma,et al. Azacitidine (AZA) with Nivolumab (Nivo), and AZA with Nivo + Ipilimumab (Ipi) in Relapsed/Refractory Acute Myeloid Leukemia: A Non-Randomized, Prospective, Phase 2 Study , 2019, Blood.
[73] M. Konopleva,et al. Clinical Profile of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) , 2019, Blood.
[74] F. Ravandi,et al. Preliminary Results from a Phase 1 First-in-Human Study of AMG 673, a Novel Half-Life Extended (HLE) Anti-CD33/CD3 BiTE® (Bispecific T-Cell Engager) in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) , 2019, Blood.
[75] P. Vyas,et al. The First-in-Class Anti-CD47 Antibody Magrolimab (5F9) in Combination with Azacitidine Is Effective in MDS and AML Patients: Ongoing Phase 1b Results , 2019, Blood.
[76] A. Harrington,et al. Lintuzumab Ac-225 in Combination with CLAG-M Chemotherapy in Relapsed/Refractory AML: Interim Results of a Phase I Study , 2019, Blood.
[77] A. Goldberg,et al. Tolerability and Efficacy of Crenolanib and Cytarabine/Anthracycline Chemotherapy in Older Patients (Aged 61 to 75) with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML) , 2019, Blood.
[78] M. Levis,et al. A Phase II Study of Midostaurin and 5-Azacitidine for Untreated Elderly and Unfit Patients With FLT3 Wild-type Acute Myelogenous Leukemia. , 2019, Clinical lymphoma, myeloma & leukemia.
[79] R. Larson,et al. Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML. , 2019, The New England journal of medicine.
[80] Kristen L. Jones,et al. DNA methyltransferase inhibition overcomes diphthamide pathway deficiencies underlying CD123-targeted treatment resistance. , 2019, The Journal of clinical investigation.
[81] P. Sharma,et al. Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study. , 2019, The Lancet. Haematology.
[82] H. Dombret,et al. Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial. , 2019, The Lancet. Oncology.
[83] M. Konopleva,et al. Tagraxofusp in Blastic Plasmacytoid Dendritic‐Cell Neoplasm , 2019, The New England journal of medicine.
[84] G. Ossenkoppele,et al. Prognostic and therapeutic role of CLEC12A in acute myeloid leukemia. , 2019, Blood reviews.
[85] P. Sharma,et al. The distribution of T‐cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia , 2018, Cancer.
[86] P. Westervelt,et al. Phase 1 First-in-Human Trial of AMV564, a Bivalent Bispecific (2:2) CD33/CD3 T-Cell Engager, in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) , 2018, Blood.
[87] P. Sharma,et al. Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study. , 2018, Cancer discovery.
[88] M. Heuser,et al. Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome , 2018, Leukemia.
[89] C. Viero,et al. Management of Cytokine Release Syndrome in AML Patients Treated with Flotetuzumab, a CD123 x CD3 Bispecific Dart® Molecule for T-Cell Redirected Therapy , 2018, Blood.
[90] S. Rutella,et al. Adaptive Immune Gene Signatures Correlate with Response to Flotetuzumab, a CD123 × CD3 Bispecific Dart® Molecule, in Patients with Relapsed/Refractory Acute Myeloid Leukemia , 2018, Blood.
[91] I. Weissman,et al. RBC-Specific CD47 Pruning Confers Protection and Underlies the Transient Anemia in Patients Treated with Anti-CD47 Antibody 5F9 , 2018, Blood.
[92] P. Paschka,et al. A Phase 1 First-in-Human Study of AMG 330, an Anti-CD33 Bispecific T-Cell Engager (BiTE®) Antibody Construct, in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) , 2018, Blood.
[93] S. Rutella,et al. Phase 1 Cohort Expansion of Flotetuzumab, a CD123×CD3 Bispecific Dart® Protein in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) , 2018, Blood.
[94] G. Uy,et al. Bispecific Antibodies for the Treatment of Acute Myeloid Leukemia , 2018, Current Hematologic Malignancy Reports.
[95] F. Ravandi,et al. A phase 1 trial of vadastuximab talirine combined with hypomethylating agents in patients with CD33-positive AML. , 2018, Blood.
[96] J. Byrd,et al. The interleukin-3 receptor CD123 targeted SL-401 mediates potent cytotoxic activity against CD34+CD123+ cells from acute myeloid leukemia/myelodysplastic syndrome patients and healthy donors , 2018, Haematologica.
[97] K. Messer,et al. A Phase I/II Trial of the Combination of Azacitidine and Gemtuzumab Ozogamicin for Treatment of Relapsed Acute Myeloid Leukemia , 2018, Clinical lymphoma, myeloma & leukemia.
[98] T. Chittenden,et al. A CD123-targeting antibody-drug conjugate, IMGN632, designed to eradicate AML while sparing normal bone marrow cells. , 2018, Blood advances.
[99] A. Letai,et al. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. , 2018, The Lancet. Oncology.
[100] F. Ravandi,et al. A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia. , 2018, Blood.
[101] Depei Wu,et al. First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia. , 2018, American journal of cancer research.
[102] Darren L. Smith,et al. Superenhancer Analysis Defines Novel Epigenomic Subtypes of Non-APL AML, Including an RARα Dependency Targetable by SY-1425, a Potent and Selective RARα Agonist. , 2017, Cancer discovery.
[103] L. Varani,et al. The Tim-3-galectin-9 Secretory Pathway is Involved in the Immune Escape of Human Acute Myeloid Leukemia Cells , 2017, EBioMedicine.
[104] F. Ravandi,et al. CASCADE: A phase 3, randomized, double-blind study of vadastuximab talirine (33A) versus placebo in combination with azacitidine or decitabine in the treatment of older patients with newly diagnosed acute myeloid leukemia (AML). , 2017 .
[105] V. Kuchroo,et al. Tim‐3 and its role in regulating anti‐tumor immunity , 2017, Immunological reviews.
[106] N. Kröger,et al. Reduction of Relapse after Unrelated Donor Stem Cell Transplantation by KIR-Based Graft Selection , 2017, Front. Immunol..
[107] Steven M. Chan,et al. Isocitrate dehydrogenase mutations in myeloid malignancies , 2016, Leukemia.
[108] M. Konopleva,et al. Results from Ongoing Phase 2 Trial of SL-401 As Consolidation Therapy in Patients with Acute Myeloid Leukemia (AML) in Remission with High Relapse Risk Including Minimal Residual Disease (MRD) , 2016 .
[109] F. Claas,et al. Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia , 2016, Science Translational Medicine.
[110] R. Hills,et al. Defining the dose of gemtuzumab ozogamicin in combination with induction chemotherapy in acute myeloid leukemia: a comparison of 3 mg/m2 with 6 mg/m2 in the NCRI AML17 Trial , 2016, Haematologica.
[111] J. Tolar,et al. IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33+ Targets While Also Inducing Persistence, In Vivo Expansion, and Enhanced Function , 2016, Clinical Cancer Research.
[112] L. Ruggeri,et al. Larger Size of Donor Alloreactive NK Cell Repertoire Correlates with Better Response to NK Cell Immunotherapy in Elderly Acute Myeloid Leukemia Patients , 2016, Clinical Cancer Research.
[113] F. Gao,et al. Targeting CD123 in acute myeloid leukemia using a T-cell-directed dual-affinity retargeting platform. , 2016, Blood.
[114] F. Hodi,et al. Ipilimumab for Patients with Relapse after Allogeneic Transplantation. , 2016, The New England journal of medicine.
[115] W. Hiddemann,et al. Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism , 2016, Leukemia.
[116] P. Moore,et al. A CD3xCD123 bispecific DART for redirecting host T cells to myelogenous leukemia: Preclinical activity and safety in nonhuman primates , 2015, Science Translational Medicine.
[117] I. Kerridge,et al. A Phase 1 study of the safety, pharmacokinetics and anti-leukemic activity of the anti-CD123 monoclonal antibody CSL360 in relapsed, refractory or high-risk acute myeloid leukemia , 2015, Leukemia & lymphoma.
[118] M. Konopleva,et al. Phase I/II trial of the combination of midostaurin (PKC412) and 5‐azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome , 2015, American journal of hematology.
[119] E. Estey,et al. Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials. , 2014, The Lancet. Oncology.
[120] M. Konopleva,et al. Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients. , 2014, Blood.
[121] A. Henn,et al. Preclinical Characterization of AMG 330, a CD3/CD33-Bispecific T-Cell–Engaging Antibody with Potential for Treatment of Acute Myelogenous Leukemia , 2014, Molecular Cancer Therapeutics.
[122] R. Kischel,et al. Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML. , 2014, Blood.
[123] E. Estey,et al. Gemtuzumab ozogamicin in combination with vorinostat and azacitidine in older patients with relapsed or refractory acute myeloid leukemia: a phase I/II study , 2014, Haematologica.
[124] D. Howard,et al. A phase 2 trial of azacitidine and gemtuzumab ozogamicin therapy in older patients with acute myeloid leukemia. , 2013, Blood.
[125] M. Meyerson,et al. Distinct pathways regulated by menin and by MLL1 in hematopoietic stem cells and developing B cells. , 2013, Blood.
[126] Huijuan Jiang,et al. CD47 is expressed abnormally on hematopoietic cells in myelodysplastic syndrome. , 2013, Leukemia research.
[127] R. Larson,et al. A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. , 2013, Blood.
[128] C. Craddock,et al. Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[129] H. Dombret,et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study , 2012, The Lancet.
[130] J. Tamburini,et al. High levels of CD34+CD38low/−CD123+ blasts are predictive of an adverse outcome in acute myeloid leukemia: a Groupe Ouest-Est des Leucémies Aiguës et Maladies du Sang (GOELAMS) study , 2011, Haematologica.
[131] M. Baccarani,et al. Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients. , 2011, Blood.
[132] M. Konopleva,et al. Phase I study of sorafenib in patients with refractory or relapsed acute leukemias , 2011, Haematologica.
[133] Luo Cheng-wei. Phase I Study of Sorafenib in Patients with Refractory or Relapsed Acute Leukemias , 2011 .
[134] Chap T Le,et al. Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia. , 2010, Blood.
[135] E. Estey,et al. Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[136] C. Pui,et al. NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[137] H. Dombret,et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[138] A. Abo,et al. Targeting C-type lectin-like molecule-1 for antibody-mediated immunotherapy in acute myeloid leukemia , 2010, Haematologica.
[139] K. Campbell,et al. 自然杀伤细胞与癌症——杀伤细胞免疫球蛋白样受体(KIR)的调控 , 2010, Zhongguo fei ai za zhi = Chinese journal of lung cancer.
[140] T. Gajewski,et al. PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model. , 2009, Blood.
[141] I. Weissman,et al. CD47 Is Upregulated on Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid Phagocytosis , 2009, Cell.
[142] Liping Yang,et al. Cytokine-induced memory-like natural killer cells , 2009, Proceedings of the National Academy of Sciences.
[143] เอกรัฐ รัฐฤทธิ์ธำรง. Loss of Mismatched HLA in Leukemia after Stem-Cell Transplantation , 2009 .
[144] A. Frankel,et al. Phase I clinical study of diphtheria toxin-interleukin 3 fusion protein in patients with acute myeloid leukemia and myelodysplasia , 2008, Leukemia & lymphoma.
[145] Marcela R. Uribe,et al. Rapid natural killer cell recovery determines outcome after T-cell-depleted HLA-identical stem cell transplantation in patients with myeloid leukemias but not with acute lymphoblastic leukemia , 2007, Leukemia.
[146] Rajiv K. Saxena,et al. Reduced expression of CD47 during murine red blood cell (RBC) senescence and its role in RBC clearance from the circulation , 2007, Transfusion.
[147] M. Martelli,et al. Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value. , 2006, Blood.
[148] G. V. van Dongen,et al. The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells. , 2005, Blood.
[149] E. Ball,et al. Cytotoxic activity of gemtuzumab ozogamicin (Mylotarg) in acute myeloid leukemia correlates with the expression of protein kinase Syk , 2006, Leukemia.
[150] H. Gundacker,et al. Age and acute myeloid leukemia. , 2006, Blood.
[151] Matthew Meyerson,et al. The Menin Tumor Suppressor Protein Is an Essential Oncogenic Cofactor for MLL-Associated Leukemogenesis , 2005, Cell.
[152] I. Bernstein,et al. Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33‐positive acute myeloid leukemia in first recurrence , 2005, Cancer.
[153] Natalia Meani,et al. Acute myeloid leukemia bearing cytoplasmic nucleophosmin (NPMc+ AML) shows a distinct gene expression profile characterized by up-regulation of genes involved in stem-cell maintenance. , 2005, Blood.
[154] C. Le,et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. , 2005, Blood.
[155] M. Linenberger,et al. CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistance , 2005, Leukemia.
[156] D. Lane,et al. Mdm2-Mediated NEDD8 Conjugation of p53 Inhibits Its Transcriptional Activity , 2004, Cell.
[157] J. Dongen,et al. High CD33-antigen loads in peripheral blood limit the efficacy of gemtuzumab ozogamicin (Mylotarg®) treatment in acute myeloid leukemia patients , 2004, Leukemia.
[158] Katia Perruccio,et al. Effectiveness of Donor Natural Killer Cell Alloreactivity in Mismatched Hematopoietic Transplants , 2002, Science.
[159] Unnur Thorsteinsdottir,et al. Defining Roles for HOX and MEIS1 Genes in Induction of Acute Myeloid Leukemia , 2001, Molecular and Cellular Biology.
[160] A. Aventín,et al. Interleukin-3 receptor alpha chain (CD123) is widely expressed in hematologic malignancies. , 2001, Haematologica.
[161] D. Howard,et al. The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells , 2000, Leukemia.
[162] M. Brizzi,et al. Interleukin 3 stimulates proliferation and triggers endothelial-leukocyte adhesion molecule 1 gene activation of human endothelial cells. , 1993, The Journal of clinical investigation.